Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer
Liquid biopsy may assist in the management of cancer patients, which can be particularly applicable in pancreatic ductal adenocarcinoma (PDAC). In this study, we investigated the utility of circulating cell-free DNA (cfDNA)-based markers as prognostic tools in metastatic PDAC. Plasma was obtained fr...
Main Authors: | Marta Toledano-Fonseca, M. Teresa Cano, Elizabeth Inga, Rosa Rodríguez-Alonso, M. Auxiliadora Gómez-España, Silvia Guil-Luna, Rafael Mena-Osuna, Juan R. de la Haba-Rodríguez, Antonio Rodríguez-Ariza, Enrique Aranda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/7/1754 |
Similar Items
-
The Combination of Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer
by: Marta Toledano-Fonseca, et al.
Published: (2021-03-01) -
Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer
by: María Victoria García-Ortiz, et al.
Published: (2023-07-01) -
Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects
by: María Victoria García-Ortiz, et al.
Published: (2023-10-01) -
<i>RAS</i> Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study
by: Chiara Nicolazzo, et al.
Published: (2022-02-01) -
Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab
by: M. José Ortiz-Morales, et al.
Published: (2022-06-01)